TABLE 1 CONVENTIONAL DIAGNOSTICS VS. DIAGNOSTIC BIOMARKER TECHNIQUES
TABLE 2 WORLDWIDE ESTIMATED INCIDENCE AND PREVALENCE OF ALL CANCER TYPES (2012)
TABLE 3 REVENUE GENERATION OF BIOLOGICAL AND TARGETED DRUGS IN 2013 ($MILLION)
TABLE 4 KEY PRODUCTS WITH THEIR PATENT EXPIRY DATES
TABLE 5 COLLABORATIONS AND ACQUISITIONS FOR DEVELOPMENT OF CANCER DRUGS
TABLE 6 PATENTS REGISTERED/APPROVED IN THE U.S., EUROPE, CANADA, CHINA, JAPAN, AND OTHERS, 2013 THROUGH 2016
TABLE 7 U.S.: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
TABLE 8 EUROPE: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
TABLE 9 CHINA: PATENT ANALYSIS BY MARKET PARTICIPANT, 2010-2016
TABLE 10 CANADA: PATENT ANALYSIS BY MARKET PARTICIPANT, 2010-2016
TABLE 11 JAPAN: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
TABLE 12 OTHERS: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
TABLE 13 CLINICAL TRIALS: CANCER BIOMARKERS
TABLE 14 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2014-2022 ($MILLION)
TABLE 15 WORLD OMICS TECHNOLOGY MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 16 WORLD OMICS TECHNOLOGY MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 17 GLOBAL GENOMICS TECHNOLOGY MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 1 GLOBAL PROTEOMICS TECHNOLOGY MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 2 GLOBAL OTHER OMICS TECHNOLOGY MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 3 GLOBAL IMAGING TECHNOLOGY MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 4 GLOBAL IMAGING TECHNOLOGY MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 5 GLOBAL IMMUNOASSAYS MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 6 GLOBAL IMMUNOASSAYS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 7 GLOBAL CYTOGENETICS-BASED TESTS MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 8 GLOBAL CYTOGENETICS-BASED TESTS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 9 GLOBAL CANCER BIOMARKERS MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 10 GLOBAL GENETIC BIOMARKERS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 11 GLOBAL PROTEIN BIOMARKERS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 12 GLOBAL GLYCO-BIOMARKERS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 13 CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2014-2022 ($MILLION)
TABLE 14 GLOBAL CANCER BIOMARKERS FOR LUNG CANCER, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 15 GLOBAL CANCER BIOMARKERS FOR BREAST CANCER, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 16 GLOBAL CANCER BIOMARKERS FOR COLORECTAL CANCER MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 17 GLOBAL CANCER BIOMARKERS FOR PROSTATE CANCER MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 18 GLOBAL CANCER BIOMARKERS FOR STOMACH CANCER MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 19 GLOBAL CANCER BIOMARKERS FOR OTHER CANCERS, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 20 CANCER BIOMARKERS MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 21 DIAGNOSTICS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 22 DRUG DISCOVERY AND DEVELOPMENT MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 23 PROGNOSTICS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 24 RISK ASSESSMENT MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 25 OTHERS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 26 CANCER BIOMARKERS MARKET, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 27 NORTH AMERICA CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2014-2022 ($MILLION)
TABLE 28 NORTH AMERICA CANCER BIOMARKERS MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 29 NORTH AMERICA CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2014-2022 ($MILLION)
TABLE 30 NORTH AMERICA CANCER BIOMARKERS MARKET, BY APPLICATION, 2014-2022 ($MILLION)
TABLE 31 NORTH AMERICAN CANCER BIOMARKERS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 32 EUROPEAN CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2014-2022 ($MILLION)
TABLE 33 EUROPEAN CANCER BIOMARKERS MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 34 EUROPEAN CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2014-2022 ($MILLION)
TABLE 35 EUROPEAN CANCER BIOMARKERS MARKET, BY APPLICATION, 2014-2022 ($MILLION)
TABLE 36 EUROPEAN CANCER BIOMARKERS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 37 ASIA-PACIFIC CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2014-2022 ($MILLION)
TABLE 38 ASIA-PACIFIC CANCER BIOMARKERS MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 39 ASIA-PACIFIC CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2014-2022 ($MILLION)
TABLE 40 ASIA-PACIFIC CANCER BIOMARKERS MARKET, BY APPLICATION, 2014-2022 ($MILLION)
TABLE 41 ASIA-PACIFIC CANCER BIOMARKERS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 42 LAMEA CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2014-2022 ($MILLION)
TABLE 43 LAMEA CANCER BIOMARKERS MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 44 LAMEA CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2014-2022 ($MILLION)
TABLE 45 LAMEA CANCER BIOMARKERS MARKET, BY APPLICATION, 2014-2022 ($MILLION)
TABLE 46 LAMEA CANCER BIOMARKERS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 47 ROCHE: COMPANY SNAPSHOT
TABLE 48 ABBOTT: COMPANY SNAPSHOT
TABLE 49 ABBOTT: OPERATING SEGMENTS
TABLE 50 GSK: COMPANY SNAPSHOT
TABLE 51 GSK: OPERATING SEGMENTS
TABLE 52 NOVARTIS: COMPANY SNAPSHOT
TABLE 53 NOVARTIS: OPERATING SEGMENTS
TABLE 54 MERCK: COMPANY SNAPSHOT
TABLE 55 MERCK: PRODUCT CATEGORIES
TABLE 56 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 57 ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 58 ELI LILLY: OPERATING SEGMENTS
TABLE 59 PFIZER, INC.: COMPANY SNAPSHOT
TABLE 60 PFIZER, INC.: OPERATING SEGMENTS
TABLE 61 QIAGEN: COMPANY SNAPSHOT
TABLE 62 GENOMIC HEALTH: COMPANY SNAPSHOT
LIST OF FIGURE
FIG. 1 CANCER BIOMARKERS MARKET: SEGMENTATION
FIG. 2 TOP IMPACTING FACTORS: CANCER BIOMARKERS MARKET, 2015-2022
FIG. 3 PERCENTAGE (%) OF NEW CANCERS CASES DIAGNOSED IN 2012
FIG. 4 TOP INVESTMENT POCKETS: CANCER BIOMARKERS, 2015-2022
FIG. 5 TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION
FIG. 6 TOP WINNING STRATEGIES: NATURE & TYPE
FIG. 7 TYPES OF STRATEGIES DISTRIBUTION
FIG. 8 DETAILED STRUCTURE OF COMPANIES AND NATURE OF STRATEGIES
FIG. 9 DETAILED STRUCTURE OF COMPANIES AND TYPE OF STRATEGIES
FIG. 10 PORTERS FIVE FORCES ANALYSIS
FIG. 11 TOP PLAYER POSITIONING, 2015
FIG. 12 PATENTS REGISTERED/APPROVED IN THE WORLD, 2013-2016
FIG. 13 U.S.: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
FIG. 14 EUROPE: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
FIG. 15 CHINA: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
FIG. 16 CANADA: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
FIG. 17 JAPAN: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
FIG. 18 OTHERS: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
FIG. 19 U.S.: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 20 CANADA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 21 MEXICO: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 22 GERMANY: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 23 U.K.: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 24 FRANCE: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 25 ITALY: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 26 RUSSIA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 27 REST OF EUROPE: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 28 JAPAN: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 29 CHINA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 30 INDIA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 31 AUSTRALIA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 32 REST OF ASIA-PACIFIC: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 33 BRAZIL: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 34 SAUDI ARABIA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 35 UAE: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 36 REST OF LAMEA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
FIG. 37 ROCHE: NET SALES, 2013-2015 ($MILLION)
FIG. 38 ROCHE: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
FIG. 39 ROCHE: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 40 ROCHE: STRATEGY SHARE, 2014-2016 (%)
FIG. 41 ABBOTT: NET SALES, 2013-2015 ($MILLION)
FIG. 42 ABBOTT: REVENUE, BY SEGMENT, 2015 (%)
FIG. 43 ABBOTT: REVENUE, BY SEGMENT, 2015 (%)
FIG. 44 ABBOTT: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 45 ABBOTT: STRATEGY SHARE, 2014-2016 (%)
FIG. 46 GSK: NET SALES, 2013-2015 ($MILLION)
FIG. 47 GSK: REVENUE, BY SEGMENT, 2015 (%)
FIG. 48 GSK: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 49 GSK: STRATEGY SHARE, 2014-2016 (%)
FIG. 50 NOVARTIS: REVENUE, 2013-2015 ($MILLION)
FIG. 51 NOVARTIS: REVENUE, BY BUSINESS SEGMENT, 2015 (%)
FIG. 52 NOVARTIS: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 53 NOVARTIS: STRATEGY SHARE, 2014-2016 (%)
FIG. 54 MERCK: NET SALES, 2013-2015 ($MILLION)
FIG. 55 MERCK: REVENUE, BY BUSINESS SEGMENT, 2015 (%)
FIG. 56 MERCK: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 57 MERCK: STRATEGY SHARE, 2014-2016 (%)
FIG. 58 BRISTOL-MYERS SQUIBB: NET SALES, 2013-2015 ($MILLION)
FIG. 59 BRISTOL-MYERS SQUIBB, REVENUE, BY GEOGRAPHY, 2015(%)
FIG. 60 BRISTOL-MYERS SQUIBB: STRATEGY SHARE, 2014-2016 (%)
FIG. 61 ELI LILLY: NET SALES, 2013-2015, ($MILLION)
FIG. 62 ELI LILLY: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
FIG. 63 ELI LILLY: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 64 ELI LILLY: STRATEGY SHARE, 2014-2016 (%)
FIG. 65 PFIZER, INC.: NET SALES, 2013-2015, ($MILLION)
FIG. 66 PFIZER, INC.: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
FIG. 67 PFIZER, INC.: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 68 PFIZER, INC.: STRATEGY SHARE, 2014-2016 (%)
FIG. 69 QIAGEN: NET SALES, 2013-2015, ($MILLION)
FIG. 70 QIAGEN: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
FIG. 71 QIAGEN: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 72 QIAGEN: STRATEGY SHARE, 2014-2016 (%)
FIG. 73 GENOMIC HEALTH: NET SALES, 2013-2015 ($MILLION)
FIG. 74 GENOMIC HEALTH: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 75 GENOMIC HEALTH: STRATEGY SHARE, 2014-2016 (%)